CYP7B1 has been demonstrated to be downregulated in NAFLD, NASH without fibrosis and T2DM but becomes up-regulated in NASH with fibrosis which may be due to an upregulation of the alternative BA pathway (Lake et al., 2013; Guillemot-Legris et al., 2016). Here, CYP7B1 is linked to metabolic dysfunction-associated steatotic liver disease.